Moreover, the targeting of carcinoembryonic antigen (CEA)-expressing cancer cells using 125I-labeled anti-CEA mAbs leads to heightened DNA damage, as evidenced by an increase in γ-H2AX foci formation, independently of apoptosis and the p53 pathways [108,109]. The gene discussed is TP53; the disease is cancer.